Natural killer cells recruited into lymph nodes inhibit alloreactive T-cell activation through perforin-mediated killing of donor allogeneic dendritic cells

被引:82
作者
Laffont, Sophie [1 ,2 ]
Seillet, Cyril [1 ,2 ]
Ortaldo, John [3 ]
Coudert, Jerome D. [1 ,2 ]
Guery, Jean-Charles [1 ,2 ]
机构
[1] Ctr Physiopathol Toulouse Purpan, INSERM, U563, Toulouse, France
[2] Univ Toulouse 3, F-31062 Toulouse, France
[3] NCI, Ctr Canc Res, Expt Immunol Lab, Frederick, MD 21701 USA
关键词
D O I
10.1182/blood-2007-10-120089
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Natural killer (NK)-cell alloreactivity is exploited in bone marrow transplantation to improve clinical outcome. Likewise, in solid organ transplantation, it has been recently shown that recipient NK cells may limit alloreactive T-cell responses through their capacity to prevent the persistence of graft-derived allogeneic dendritic cells (DCs). In a model of CD4+ T cell-mediated allogeneic skin graft rejection, we show that the absence of host NK-cell alloreactivity was characterized by enhanced expansion of alloreactive effector T lymphocytes, including Th2 cells, and massive eosinophilic infiltrates in the rejected tissues. In CD8+ T celldeficient C57BL/6 (H-2b) recipients injected with allogeneic BALB/c (H-2d) DCs, we demonstrated that NK cells expressing the H-2Dd-specific Ly49D activating receptor were implicated in the regulation of alloreactive CD4+ T-cell responses. Moreover, we showed that Ly49D+ CD127NK cells were recruited within DC drain- ing lymph nodes and rapidly eliminated allogeneic H-2d DCs through the perforin pathway. In normal mice, we further demonstrated that NK cells by quickly eliminating allogeneic DCs strongly inhibited alloreactive CD8+ T-cell responses. Thus, NK cells act as early regulators of alloreactive T-cell priming in allotransplantation through their capacity to kill allogeneic DCs in draining lymph nodes.
引用
收藏
页码:661 / 671
页数:11
相关论文
共 40 条
[1]   Natural killer cell behavior in lymph nodes revealed by static and real-time imaging [J].
Bajénoff, M ;
Breart, B ;
Huang, AYC ;
Qi, H ;
Cazareth, J ;
Braud, VM ;
Germain, RN ;
Glaichenhaus, N .
JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (03) :619-631
[2]   NK cells promote islet allograft tolerance via a perforin-dependent mechanism [J].
Beilke, JN ;
Kuhl, NR ;
Van Kaer, L ;
Gill, RG .
NATURE MEDICINE, 2005, 11 (10) :1059-1065
[3]   Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment [J].
Chen, SH ;
Kawashima, H ;
Lowe, JB ;
Lanier, LL ;
Fukuda, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (12) :1679-1689
[4]   NK cell and DC interactions [J].
Cooper, MA ;
Fehniger, TA ;
Fuchs, A ;
Colonna, M ;
Caligiuri, MA .
TRENDS IN IMMUNOLOGY, 2004, 25 (01) :47-52
[5]   Preventing NK cell activation by donor dendritic cells enhances allospecific CD4 T cell priming and promotes Th type 2 responses to transplantation antigens [J].
Coudert, RD ;
Coureau, C ;
Guéry, JC .
JOURNAL OF IMMUNOLOGY, 2002, 169 (06) :2979-2987
[6]   CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2:: a potential new link between adaptive and innate immunity [J].
Fehniger, TA ;
Cooper, MA ;
Nuovo, GJ ;
Cella, M ;
Facchetti, F ;
Colonna, M ;
Caligiuri, MA .
BLOOD, 2003, 101 (08) :3052-3057
[7]   NK cell compartments and their activation by dendritic cells [J].
Ferlazzo, G ;
Münz, C .
JOURNAL OF IMMUNOLOGY, 2004, 172 (03) :1333-1339
[8]   Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs [J].
Ferlazzo, G ;
Pack, M ;
Thomas, D ;
Paludan, C ;
Schmid, D ;
Strowig, T ;
Bougras, G ;
Muller, WA ;
Moretta, L ;
Münz, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (47) :16606-16611
[9]   Dendritic cells prime in vivo alloreactive CD4 T lymphocytes toward type 2 cytokine- and TGF-β-producing cells in the absence of CD8 T cell activation [J].
Foucras, G ;
Coudert, JD ;
Coureau, C ;
Guéry, JC .
JOURNAL OF IMMUNOLOGY, 2000, 165 (09) :4994-5003
[10]  
George TC, 1999, J IMMUNOL, V162, P2035